

Efficient Strategy for the Synthesis of Stereopentad Subunits of Scytophycin, Rifamycin S, and Discodermolide


S. BouzBouz* and J. Cossy*

Laboratoire de Chimie Organique associé au CNRS, ESPCI, 10 rue Vauquelin,
75231 - Paris Cedex 05, France

janine.cossy@espci.fr

Received June 8, 2001 (Revised Manuscript Received October 30, 2001)

ABSTRACT



An efficient, simple method has been developed for the stereocontrolled synthesis of polypropionate stereopentads in high enantio- and diastereomeric purities.

The polypropionates (chains with alternating methyl–hydroxy–methyl substituents)¹ represent an important class of natural products such as the macrolides and the ionophores,² which are often associated with a broad spectrum of biological activity. Their name comes from their biogenesis, which entails the iterative condensation of propionate units.³ Several stereoselective methods and strategies have been developed to provide access to these systems which possess a high density of stereogenic centers.^{4,5}

The presence of more than one stereopentad encompassing multiple contiguous stereogenic centers and the control of absolute stereochemistry in a given molecule presents a major challenge in stereoselective synthesis. In looking for routes

to prepare advanced stereopentad segments, our interest was drawn to *meso*-dialdehydes.⁶ The asymmetric transformation of *meso* compounds by reaction with a chiral reagent is a generally useful strategy for asymmetric synthesis, and in recent years several reactions of this type involving either enzymatic catalysis or nonenzymatic reactions have been reported.⁷

We report here the direct transformation of *meso*-dialdehydes **1a** and **1b** to stereopentad subunits by using the cyclopentadienyldialkoxycrotyltitanium⁸ complexes (*R,R*)-**II** and (*S,S*)-**II** and their further elaboration to common polypropionate subunits present in different natural products

(1) Hoffmann, R. W. *Angew. Chem., Int. Ed. Engl.* **1987**, 26, 489.

(2) For reviews, see: (a) O'Hagen, D. *The Polyketide Metabolites*; Ellis Horwood: Chichester, 1991. (b) Schummer, D.; Böhlendorf, B.; Kiffe, M.; Höfle, G. In *Antibiotics and Antiviral Compounds*; Krohn, K., Kirst, H. A., Maag, H., Eds.; VCH: Weinheim, 1993. (c) O'Hagen, D. *Nat. Prod. Rep.* **1995**, 12, 1. (d) Dutton, C. J.; Banks, B. J.; Cooper, C. B. *Nat. Prod. Rep.* **1995**, 12, 165.

(3) See, for example: (a) Corey, E. J.; Cheng, X. M. *The Logic of Chemical Synthesis*; Wiley: New York, 1989. (b) *The Total Synthesis of Natural Products*; Ap Simon, J. A., Ed.; Wiley: New York, Vols. 1–8. (c) *Studies in Natural Product Synthesis*; Atta-ur-Rahman, Ed.; Elsevier: Amsterdam, Vols. 1–13. (d) *Recent Progress in The Chemical Synthesis of Antibiotics and Related Microbial Products*; Lukacs, G., Ed.; Springer-Verlag: Heidelberg, 1993; Vol. 2. (e) *Macrolides-Chemistry, Pharmacology and Clinical Uses*; Bryskier, A. J., Butzler, J.-P., Neu, H. C., Tulkens, P. M., Eds.; Arnette Blackwell: Paris, 1993. (f) *Antibiotics and Antiviral Compounds, Chemical Synthesis and Modification*; Krohn, K., Kirst, H. A., Maag, H., Eds.; VCH: Weinheim, 1993.

(4) (a) Evans, D. A. *Aldrichimica Acta* **1982**, 15, 23. (b) Masamune, S.; Choy, W. *Aldrichimica Acta* **1982**, 15, 47. (c) Mukaiyama, T. *Org. React.* **1982**, 28, 103. (d) Hoffmann, R. W. *Angew. Chem., Int. Ed. Engl.* **1982**, 21, 555. (e) Heathcock, C. H. *Aldrichimica Acta* **1990**, 23, 99. (f) Paterson, I.; Channon, J. A. *Tetrahedron Lett.* **1992**, 33, 797. (g) Paterson, I.; Yeung, K. S. *Tetrahedron Lett.* **1993**, 34, 5347. (h) Szymoniak, J.; Lefranc, H.; Moïse, C. *J. Org. Chem.* **1996**, 61, 3926. (i) Marshall, J. A.; Palovich, M. R. *J. Org. Chem.* **1998**, 63, 3701. (j) Marshall, J. A.; Fitzgerald, R. N. *J. Org. Chem.* **1999**, 64, 4477.

(5) (a) Danishefsky, S. J. *Aldrichimica Acta* **1986**, 19, 59. (b) Hanessian, S. *Aldrichimica Acta* **1989**, 22, 3. (c) Marshall, J. A.; Perkins, J. F.; Wolf, M. A. *J. Org. Chem.* **1995**, 60, 5556. (d) Vogel, P.; Sevin, A.-F.; Kernien, P.; Bialecki, M. *Pure Appl. Chem.* **1996**, 68, 719. (e) Jain, N. F.; Takenaka, N.; Panek, J. S. *J. Am. Chem. Soc.* **1996**, 118, 12475.

(6) De Brabander, J.; Oppolzer, W. *Tetrahedron* **1997**, 53, 9169.

(7) Kann, N.; Rein, T. *J. Org. Chem.* **1993**, 58, 3802 and references therein.

(8) Hafner, A.; Duthaler, R. O.; Marti, R.; Rihs, J.; Rothe-Streit, P.; Schwarzenbach, F. *J. Am. Chem. Soc.* **1992**, 114, 2321.





Figure 1.

such as scytophycin,⁹ rifamycin S,¹⁰ and discodermolide¹¹ (Figure 1).


Treatment of dialdehyde **1a** with one equivalent of crotyltitanium complex (*R,R*)-**II** and (*S,S*)-**II** was first examined. The hemiketals **2a** and **2b** were respectively obtained, and these crude products were treated with NaBH₄

to produce stereopentads **3a**¹² (54% from **1a**) and **3b**¹² (56% from **1a**). It is worth noting that in these experiments the double addition products were not observed (Scheme 1).

The relative stereochemistry between the different groups present in **3a** and **3b** was determined after transformation of these compounds to the corresponding acetonides **6a** and




6b. Esterification of the primary alcohol **3a** with pivaloyl chloride led to **4a** in 91% yield, followed by treatment of compound **4a** with tetra-*n*-butylammonium fluoride (*n*Bu₄NF) (94%). Subsequent protection of diol **5a** with 2,2-dimethoxypropane in the presence of CSA in acetone afford the acetonide **6a** in 92% yield. A similar reaction sequence was applied to stereopentad **3b** to afford acetonide **6b** (Scheme 2). The relative stereochemistry of the *anti*-1,3-




diol in **6a** and **6b** was confirmed by analyzing the ¹³C NMR chemical shift ($\delta = 25.0, 23.2$ for Me₂C).¹³ The only product obtained in each case was the Felkin–Anh product.

The absolute configuration at C2, C3, C4, C5, and C6 in **3a** was determined after transformation of compound **6a** to the corresponding acetonide **7a** (Scheme 3). After reduction



of **6a** with LiAlH₄ and protection of the primary alcohol by using TBDPSCl (DMF, imidazole), compound **7a** was obtained in 82% yield ($[\alpha]^{22}_D = +16.1, c 1.1, \text{CHCl}_3$; lit.¹⁴ $[\alpha]^{22}_D = +18.1, c 1.4, \text{CHCl}_3$). This chemical correlation allowed us to attribute the configuration 2*S*,3*S*,4*S*,5*S*,6*S* to compound **3a**. The stereopentad **3a** corresponds to the C19–C25 fragment of scytophyecin and to the C4–C10 fragment of rifamycin S.

(9) Paterson, I.; Watson, C.; Yeung, K.-S.; Ward, R. A.; Wallace, P. A. *Tetrahedron* **1998**, *54*, 11935 and 11955.



The stereopentad **9** present in the C15–C21 fragment of (+)-discodermolide was synthesized from the *meso*-dialdehyde **1b**¹⁵ by using the cyclopentadienyldialkoxyacrylyl-titanium complex (*R,R*)-**II**. When dialdehyde **1b** was treated with (*R,R*)-**II**, lactol **8** was obtained and directly reduced with NaBH₄ (MeOH, 0 °C) to afford the stereopentad **9** in 58% yield. This compound was then transformed to acetonide **11** in three steps. After protection of the primary alcohol by using pivaloyl chloride (PivCl, pyridine, 25 °C), ester **10** was treated with *n*Bu₄NF and the diol was protected under the standard conditions (CSA, acetone, DMP) to produce the acetonide **11** in 85% yield. The *syn* relative configuration of the hydroxy groups at C3 and C5 was confirmed by the analysis of the ¹³C NMR spectra ($\delta = 19.2, 29.8$ for Me₂C).¹³ The absolute configuration of the stereogenic centers was determined after transformation of **11** to **12** and by comparison of the $[\alpha]_D$ ($[\alpha]^{22}_D = +21, c 1.4, \text{CHCl}_3$; lit.¹⁶ $[\alpha]^{22}_D = +23.4, c 1.37, \text{CHCl}_3$) (Scheme 4).

As previously observed in the desymmetrization of *meso*-dialdehydes by cyclopentadienyldialkoxyallyltitanium com-

(10) Hanessian, S.; Wang, W.; Yonghua, G.; Olivier, E. *J. Am. Chem. Soc.* **1997**, *119*, 10034 and references therein.

(11) (a) Smith, A. B., III; Kaufman, M. D.; Beauchamp, T. J.; LaMarche, M. J.; Arimoto, H. *Org. Lett.* **1999**, *1*, 1823 and references therein. (b) Paterson, I.; Gordon, J. F. *Tetrahedron Lett.* **2000**, *41*, 6935.

(12) The diastereoselectivity was determined by ¹H NMR and by GC/MS.

(13) Rychnovsky, S. D.; Skalitzky, D. J. *Tetrahedron Lett.* **1990**, *31*, 945.

(14) Roush, W. R.; Palkowitz, A. D.; Ando, K. *J. Am. Chem. Soc.* **1990**, *112*, 6348.

(15) (a) Prepared from the corresponding monoprotected triol. Harada, T.; Inoue, A.; Wada, I.; Uchimura, J.-J.; Tanaka, S.; Oku, A. *J. Am. Chem. Soc.* **1993**, *115*, 7665. (b) ¹H NMR of **1b** δ : 9.80 (s, 2H), 4.56 (t, *J* = 4.4 Hz, 1H), 2.57 (m, 2H), 1.11 (d, *J* = 7.0 Hz, 6H), 0.88 (s, 9H), 0.08 (s, 6H).

(16) Panek, J. S.; Takenaka, N.; Hu, T. *J. Am. Chem. Soc.* **1999**, *121*, 9229.

plexes,¹⁷ the cyclopentadienyldialkoxytitanium complexes (*R,R*)-**II** and (*S,S*)-**II** discriminate respectively the *pro*-(*S*) and the *pro*-(*R*) faces of *meso*-dialdehydes. The desymmetrization of *meso*-dialdehydes by the complexes (*R,R*)-**II** and (*S,S*)-**II** allow a short and efficient synthesis of stereopentads which are present in biologically active natural products.

(17) BouzBouz, S.; Popkin, M. E.; Cossy, J. *Org. Lett.* **2000**, 2, 3449.

Acknowledgment. COST D13/010/00 is acknowledged for support and Eli Lilly (Indianapolis, IN) is greatly acknowledged for financial support.

Supporting Information Available: Experimental procedure, analytical and spectroscopic data for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL016250H